D. E. Shaw & Co., Inc. Otonomy, Inc. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.58 - $4.06 $1.07 Million - $2.74 Million	-675,400 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.13 - $3.83 $330,904 - $595,005	-155,354 Reduced 18.7%	675,400 $2.59 Million
Q2 2019 Aug 14, 2019	SELL	$2.35 - $3.09 $23,767 - $31,252	-10,114 Reduced 1.2%	830,754 $2.29 Million
Q1 2019 May 15, 2019	SELL	$1.8 - $2.97 $34,146 - $56,340	-18,970 Reduced 2.21%	840,868 $2.21 Million
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $57,630 - $111,826	-38,166 Reduced 4.25%	859,838 $1.59 Million
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $36,342 - $55,213	13,978 Added 1.58%	898,004 $2.47 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $247,226 - $317,385	66,818 Added 8.18%	884,026 $3.4 Million
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $356 - $536	-88 Reduced 0.01%	817,208 $3.43 Million
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $2.01 Million - $3.98 Million	716,783 Added 713.12%	817,296 $4.54 Million
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $321,641 - $2.09 Million	100,513	100,513 $327,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.